Lead Plaintiff Deadline is April 21, 2026
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against on behalf of all persons and entities that purchased or otherwise Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept” or the ‘Company”) securities between October 31, 2024 and December 30, 2025, both dates inclusive (the “Class Period”). Investors have until April 21, 2026, to seek appointments as lead plaintiff.
PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION
Corcept Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
1. Defendants overstated the strength of the clinical trials supporting relacorilant by representing them as “powerful support” for Corcept’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”);
2. Defendants falsely conveyed confidence in relacorilant’s regulatory prospects by claiming they had communicated with the FDA, foresaw no impediments to approval, and repeatedly told investors that “relacorilant is approaching approval,” when, in fact, the FDA had repeatedly raised concerns regarding the adequacy of the clinical evidence supporting the NDA; and
3. As a result of the foregoing, Defendants failed to disclose the known and material risk that Corcept’s relacorilant NDA would not be approved, rendering their statements about the Company’s business, operations, and prospects materially false and misleading at all relevant times.
Investors who suffered losses have until April 21, 2026 to seek appointment as lead plaintiff.
Why Wolf Haldenstein Adler Freeman & Herz LLP?:
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
Contact:
- Phone: (800) 575-0735 or (212) 545-4774
-
Email:
[email protected] - Contact Person: Gregory Stone, Director of Case and Financial Analysis
Firm Website:
Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
